KOPENHAGEN, Dänemark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) und AbbVie (NYSE: ABBV) gaben heute eine Klarstellung zu den primären Endpunkten der Phase‑3‑EPCORE®‑DLBCL‑1‑Studie bekannt, in der die Monotherapie epcoritamab (DuoBody®‑CD3xCD20), ein subkutan verabreichtes, T‑Zell‑aktivierendes bispezifisches Antikörperpräparat, im Vergleich zur vom Prüfarzt gewählten Chem...
Company Announcement Net sales of DARZALEX ® in the second quarter of 2026 totaled USD 4,207 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 15, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) prod...
KOPENHAGEN, Dänemark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) gab heute bekannt, dass die Europäische Kommission (EC) die Marktzulassung für TEPKINLY® (epcoritamab) in Kombination mit lenalidomid und rituximab (TEPKINLY + R2) für die Behandlung erwachsener Patienten mit rezidiviertem oder refraktärem (R/R) follikulärem Lymphom (FL) erteilt hat. Die Zulassung basiert auf Ergebnissen der zulas...
The Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met the primary goal in a late-stage clinical trial.
Company Announcement Topline results from Phase 3 EPCORE ® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) EPCORE DLBCL-4 demonstrated improved PFS with a chemotherapy-free combination tr...
Company Announcement COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 185 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others.
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 15, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that through shares, as of June 12, 2026, Orbis Investment Management Limited controlled the voting rights to 3,112,476 shares in Genmab...